LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Fukui, Mototaka"
  2. AU="Jones, Clare A"
  3. AU="Chen, Yonghua"
  4. AU=Das Nilay Kanti
  5. AU="Christine Brittsan"
  6. AU="Skinner, Henry"
  7. AU=Wang Wan-Ying
  8. AU="Ingrid Natalia Muñoz Quijano"
  9. AU="Xu, Jianrong"
  10. AU="Klutts, Abigail"
  11. AU="Corumlu, Ufuk"
  12. AU="Frank Dickmann"
  13. AU="Paz-Priel, Ido"
  14. AU=Budhraja Anshul

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel: Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study.

    Tanimura, Keiko / Takeda, Takayuki / Yoshimura, Akihiro / Honda, Ryoichi / Goda, Shiho / Shiotsu, Shinsuke / Fukui, Mototaka / Chihara, Yusuke / Uryu, Kiyoaki / Takei, Shota / Katayama, Yuki / Hibino, Makoto / Yamada, Tadaaki / Takayama, Koichi

    Cancers

    2023  Band 15, Heft 17

    Abstract: Background: Durvalumab consolidation after chemoradiotherapy (CRT) is a standard treatment for locally advanced non-small cell lung cancer (NSCLC). However, studies on immunological and nutritional markers to predict progression-free survival (PFS) and ... ...

    Abstract Background: Durvalumab consolidation after chemoradiotherapy (CRT) is a standard treatment for locally advanced non-small cell lung cancer (NSCLC). However, studies on immunological and nutritional markers to predict progression-free survival (PFS) and overall survival (OS) are inadequate. Systemic inflammation causes cancer cachexia and negatively affects immunotherapy efficacy, which also reflects survival outcomes.
    Patients and methods: We retrospectively investigated 126 patients from seven institutes in Japan.
    Results: The modified Glasgow Prognostic Score (mGPS) values, before and after CRT, were the essential predictors among the evaluated indices. A systemic inflammation-based prognostic risk classification was created by combining mGPS values before CRT, and C-reactive protein (CRP) levels after CRT, to distinguish tumor-derived inflammation from CRT-induced inflammation. Patients were classified into high-risk (
    Conclusion: Combining pre-CRT mGPS values with post-CRT CRP levels in patients with locally advanced NSCLC helps to predict the PFS and OS of durvalumab consolidation after CRT.
    Sprache Englisch
    Erscheinungsdatum 2023-09-01
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15174358
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: COVID-19 vaccination: effective utilization of low dead space (LDS) syringes.

    Shinozuka, Jun / Hata, Michiaki / Eguchi, Hiromi / Mori, Masahiro / Eguchi, Mitsunori / Fukui, Mototaka / Sai, Natsuki / Imashuku, Shinsaku / Sueyoshi, Atsushi

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

    2021  Band 113, Seite(n) 90–92

    Mesh-Begriff(e) COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Syringes ; Vaccination
    Chemische Substanzen COVID-19 Vaccines
    Sprache Englisch
    Erscheinungsdatum 2021-09-29
    Erscheinungsland Canada
    Dokumenttyp Journal Article
    ZDB-ID 1331197-9
    ISSN 1878-3511 ; 1201-9712
    ISSN (online) 1878-3511
    ISSN 1201-9712
    DOI 10.1016/j.ijid.2021.09.068
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4516: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel: Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.

    Yoshimura, Akihiro / Takeda, Takayuki / Kataoka, Nobutaka / Tanimura, Keiko / Fukui, Mototaka / Chihara, Yusuke / Takei, Shota / Kawachi, Hayato / Nakanishi, Kentaro / Yamanaka, Yuta / Tamiya, Nobuyo / Honda, Ryoichi / Okura, Naoko / Yamada, Takahiro / Uryu, Kiyoaki / Murai, Junji / Shiotsu, Shinsuke / Yoshioka, Hiroshige / Yamada, Tadaaki /
    Kurata, Takayasu / Takayama, Koichi

    Frontiers in oncology

    2024  Band 14, Seite(n) 1303543

    Abstract: Introduction: The efficacy of second-line immune checkpoint inhibitor (ICI) therapy is limited in non-small cell lung cancer (NSCLC) patients with ≤ 49% PD-L1 expression. Although chemoimmunotherapy is a promising strategy, platinum-based chemotherapy ... ...

    Abstract Introduction: The efficacy of second-line immune checkpoint inhibitor (ICI) therapy is limited in non-small cell lung cancer (NSCLC) patients with ≤ 49% PD-L1 expression. Although chemoimmunotherapy is a promising strategy, platinum-based chemotherapy followed by ICI monotherapy is often used to avoid synergistic adverse events. However, predictors of the efficacy of ICI monotherapy after platinum-based chemotherapy in NSCLC with ≤ 49% PD-L1 expression remain scarce.
    Methods: This multicenter retrospective study evaluated 54 advanced or recurrent NSCLC patients with ≤ 49% PD-L1 expression who were treated with second-line ICI monotherapy following disease progression on first-line platinum-based chemotherapy at nine hospitals in Japan. The impact of response to platinum-based chemotherapy on the efficacy of subsequent ICI monotherapy was investigated.
    Results: The response to first-line platinum-based chemotherapy was divided into two groups: the non-progressive disease (PD) group, which included patients who did not experience disease progression after four cycles of chemotherapy, and the PD group, which included patients who showed initial PD or could not maintain disease control during the four cycles of chemotherapy and switched to second-line ICI monotherapy. Among the 54 patients, 32 and 22 were classified into the non-PD and PD groups, respectively. The non-PD group showed better response rates (p = 0.038) and longer overall survival (OS) with ICI monotherapy (p = 0.023) than the PD group. Multivariate analysis identified that maintaining a non-PD status after four cycles of chemotherapy was an independent prognostic factor for ICI monotherapy (p = 0.046). Moreover, patients with a modified Glasgow Prognostic Score (mGPS) of 0 showed a tendency for longer OS with ICI monotherapy (p = 0.079), and there was a significant correlation between maintaining non-PD after four cycles of chemotherapy and an mGPS of 0 (p = 0.045).
    Conclusion: Maintaining a non-PD status after four cycles of platinum-based chemotherapy was a predictor of OS after second-line ICI monotherapy. These findings will help physicians select the most suitable treatment option for NSCLC patients who were treated with platinum-based chemotherapy and switched to second-line treatment. Those who experienced early PD during platinum-based chemotherapy should not be treated with ICI monotherapy in the second-line setting.
    Sprache Englisch
    Erscheinungsdatum 2024-01-26
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2024.1303543
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel: First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.

    Tanimura, Keiko / Takeda, Takayuki / Kataoka, Nobutaka / Yoshimura, Akihiro / Nakanishi, Kentaro / Yamanaka, Yuta / Yoshioka, Hiroshige / Honda, Ryoichi / Uryu, Kiyoaki / Fukui, Mototaka / Chihara, Yusuke / Takei, Shota / Kawachi, Hayato / Yamada, Tadaaki / Tamiya, Nobuyo / Okura, Naoko / Yamada, Takahiro / Murai, Junji / Shiotsu, Shinsuke /
    Kurata, Takayasu / Takayama, Koichi

    Cancers

    2023  Band 15, Heft 20

    Abstract: Background: The long overall survival (OS) observed among patients with non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression in chemoimmunotherapy (CIT) groups in previous phase III trials suggests the limited ... ...

    Abstract Background: The long overall survival (OS) observed among patients with non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression in chemoimmunotherapy (CIT) groups in previous phase III trials suggests the limited efficacy of CIT among the subgroup with ≤49% PD-L1 expression on tumor cells. Hence, sequential treatment with first-line platinum-based chemotherapy followed by second-line immune checkpoint inhibitor treatment (SEQ) is an option. This study examined whether first-line CIT would provide better outcomes than SEQ in patients with advanced NSCLC with ≤49% PD-L1 expression.
    Methods: This retrospective study evaluated patients with untreated NSCLC who received first-line CIT or SEQ at nine hospitals in Japan. OS, progression-free survival (PFS), PFS-2 (the time from first-line treatment to progression to second-line treatment or death), and other related outcomes were evaluated between the CIT and SEQ groups.
    Results: Among the 305 enrolled patients, 234 eligible patients were analyzed: 165 in the CIT group and 69 in the SEQ group. The COX proportional hazards model suggested a significant interaction between PD-L1 expression and OS (
    Conclusions: CIT is recommended for patients with NSCLC with 1-49% PD-L1 expression because it significantly improved OS and PFS compared to SEQ. CIT had limited benefits in patients with <1% PD-L1 expression, and the median PFS-2 in the SEQ group was significantly longer than the median PFS in the CIT group. These findings will help physicians select the most suitable treatment option for patients with NSCLC, considering PD-L1 expressions.
    Sprache Englisch
    Erscheinungsdatum 2023-10-14
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15204988
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study.

    Nakagawara, Kensuke / Kamata, Hirofumi / Chubachi, Shotaro / Namkoong, Ho / Tanaka, Hiromu / Lee, Ho / Otake, Shiro / Fukushima, Takahiro / Kusumoto, Tatsuya / Morita, Atsuho / Azekawa, Shuhei / Watase, Mayuko / Asakura, Takanori / Masaki, Katsunori / Ishii, Makoto / Endo, Akifumi / Koike, Ryuji / Ishikura, Hiroyasu / Takata, Tohru /
    Matsushita, Yasushi / Harada, Norihiro / Kokutou, Hiroyuki / Yoshiyama, Takashi / Kataoka, Kensuke / Mutoh, Yoshikazu / Miyawaki, Masayoshi / Ueda, Soichiro / Ono, Hiroshi / Ono, Takuya / Shoko, Tomohisa / Muranaka, Hiroyuki / Kawamura, Kodai / Mori, Nobuaki / Mochimaru, Takao / Fukui, Mototaka / Chihara, Yusuke / Nagasaki, Yoji / Okamoto, Masaki / Amishima, Masaru / Odani, Toshio / Tani, Mayuko / Nishi, Koichi / Shirai, Yuya / Edahiro, Ryuya / Ando, Akira / Hashimoto, Naozumi / Ogura, Shinji / Kitagawa, Yuichiro / Kita, Toshiyuki / Kagaya, Takashi / Kimura, Yasuhiro / Miyazawa, Naoki / Tsuchida, Tomoya / Fujitani, Shigeki / Murakami, Koji / Sano, Hirohito / Sato, Yuki / Tanino, Yoshinori / Otsuki, Ryo / Mashimo, Shuko / Kuramochi, Mizuki / Hosoda, Yasuo / Hasegawa, Yoshinori / Ueda, Tetsuya / Takaku, Yotaro / Ishiguro, Takashi / Fujiwara, Akiko / Kuwahara, Naota / Kitamura, Hideya / Hagiwara, Eri / Nakamori, Yasushi / Saito, Fukuki / Kono, Yuta / Abe, Shinji / Ishii, Tomoo / Ohba, Takehiko / Kusaka, Yu / Watanabe, Hiroko / Masuda, Makoto / Watanabe, Hiroki / Kimizuka, Yoshifumi / Kawana, Akihiko / Kasamatsu, Yu / Hashimoto, Satoru / Okada, Yukinori / Takano, Tomomi / Katayama, Kazuhiko / Ai, Masumi / Kumanogoh, Atsushi / Sato, Toshiro / Tokunaga, Katsushi / Imoto, Seiya / Kitagawa, Yuko / Kimura, Akinori / Miyano, Satoru / Hasegawa, Naoki / Ogawa, Seishi / Kanai, Takanori / Fukunaga, Koichi

    BMC pulmonary medicine

    2023  Band 23, Heft 1, Seite(n) 146

    Abstract: Background: Although cases of respiratory bacterial infections associated with coronavirus disease 2019 (COVID-19) have often been reported, their impact on the clinical course remains unclear. Herein, we evaluated and analyzed the complication rates of ...

    Abstract Background: Although cases of respiratory bacterial infections associated with coronavirus disease 2019 (COVID-19) have often been reported, their impact on the clinical course remains unclear. Herein, we evaluated and analyzed the complication rates of bacterial infections, causative organisms, patient backgrounds, and clinical outcome in Japanese patients with COVID-19.
    Methods: We performed a retrospective cohort study that included inpatients with COVID-19 from multiple centers participating in the Japan COVID-19 Taskforce (April 2020 to May 2021) and obtained demographic, epidemiological, and microbiological results and the clinical course and analyzed the cases of COVID-19 complicated by respiratory bacterial infections.
    Results: Of the 1,863 patients with COVID-19 included in the analysis, 140 (7.5%) had respiratory bacterial infections. Community-acquired co-infection at COVID-19 diagnosis was uncommon (55/1,863, 3.0%) and was mainly caused by Staphylococcus aureus, Klebsiella pneumoniae and Streptococcus pneumoniae. Hospital-acquired bacterial secondary infections, mostly caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia, were diagnosed in 86 patients (4.6%). Severity-associated comorbidities were frequently observed in hospital-acquired secondary infection cases, including hypertension, diabetes, and chronic kidney disease. The study results suggest that the neutrophil-lymphocyte ratio (> 5.28) may be useful in diagnosing complications of respiratory bacterial infections. COVID-19 patients with community-acquired or hospital-acquired secondary infections had significantly increased mortality.
    Conclusions: Respiratory bacterial co-infections and secondary infections are uncommon in patients with COVID-19 but may worsen outcomes. Assessment of bacterial complications is important in hospitalized patients with COVID-19, and the study findings are meaningful for the appropriate use of antimicrobial agents and management strategies.
    Mesh-Begriff(e) Humans ; COVID-19/complications ; COVID-19/epidemiology ; SARS-CoV-2 ; Retrospective Studies ; Coinfection/epidemiology ; COVID-19 Testing ; East Asian People ; Bacterial Infections/epidemiology ; Bacterial Infections/microbiology ; Respiratory Tract Infections/epidemiology ; Staphylococcal Infections ; Cross Infection ; Community-Acquired Infections/epidemiology ; Disease Progression
    Sprache Englisch
    Erscheinungsdatum 2023-04-26
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2059871-3
    ISSN 1471-2466 ; 1471-2466
    ISSN (online) 1471-2466
    ISSN 1471-2466
    DOI 10.1186/s12890-023-02418-3
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Diagnostic significance of secondary bacteremia in patients with COVID-19.

    Nakagawara, Kensuke / Kamata, Hirofumi / Chubachi, Shotaro / Namkoong, Ho / Tanaka, Hiromu / Lee, Ho / Otake, Shiro / Fukushima, Takahiro / Kusumoto, Tatsuya / Morita, Atsuho / Azekawa, Shuhei / Watase, Mayuko / Asakura, Takanori / Masaki, Katsunori / Ishii, Makoto / Endo, Akifumi / Koike, Ryuji / Ishikura, Hiroyasu / Takata, Tohru /
    Matsushita, Yasushi / Harada, Norihiro / Kokutou, Hiroyuki / Yoshiyama, Takashi / Kataoka, Kensuke / Mutoh, Yoshikazu / Miyawaki, Masayoshi / Ueda, Soichiro / Ono, Hiroshi / Ono, Takuya / Shoko, Tomohisa / Muranaka, Hiroyuki / Kawamura, Kodai / Mori, Nobuaki / Mochimaru, Takao / Fukui, Mototaka / Chihara, Yusuke / Nagasaki, Yoji / Okamoto, Masaki / Amishima, Masaru / Odani, Toshio / Tani, Mayuko / Nishi, Koichi / Shirai, Yuya / Edahiro, Ryuya / Ando, Akira / Hashimoto, Naozumi / Ogura, Shinji / Kitagawa, Yuichiro / Kita, Toshiyuki / Kagaya, Takashi / Kimura, Yasuhiro / Miyazawa, Naoki / Tsuchida, Tomoya / Fujitani, Shigeki / Murakami, Koji / Sano, Hirohito / Sato, Yuki / Tanino, Yoshinori / Otsuki, Ryo / Mashimo, Shuko / Kuramochi, Mizuki / Hosoda, Yasuo / Hasegawa, Yoshinori / Ueda, Tetsuya / Takaku, Yotaro / Ishiguro, Takashi / Fujiwara, Akiko / Kuwahara, Naota / Kitamura, Hideya / Hagiwara, Eri / Nakamori, Yasushi / Saito, Fukuki / Kono, Yuta / Abe, Shinji / Ishii, Tomoo / Ohba, Takehiko / Kusaka, Yu / Watanabe, Hiroko / Masuda, Makoto / Watanabe, Hiroki / Kimizuka, Yoshifumi / Kawana, Akihiko / Kasamatsu, Yu / Hashimoto, Satoru / Okada, Yukinori / Takano, Tomomi / Katayama, Kazuhiko / Ai, Masumi / Kumanogoh, Atsushi / Sato, Toshiro / Tokunaga, Katsushi / Imoto, Seiya / Kitagawa, Yuko / Kimura, Akinori / Miyano, Satoru / Hasegawa, Naoki / Ogawa, Seishi / Kanai, Takanori / Fukunaga, Koichi

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

    2023  Band 29, Heft 4, Seite(n) 422–426

    Abstract: Objectives: We investigated the occurrence of non-respiratory bacterial and fungal secondary infections, causative organisms, impact on clinical outcomes, and association between the secondary pathogens and mortality in hospitalized patients with ... ...

    Abstract Objectives: We investigated the occurrence of non-respiratory bacterial and fungal secondary infections, causative organisms, impact on clinical outcomes, and association between the secondary pathogens and mortality in hospitalized patients with coronavirus disease 2019 (COVID-19).
    Methods: This was a retrospective cohort study that included data from inpatients with COVID-19 from multiple centers participating in the Japan COVID-19 Taskforce (April 2020 to May 2021). We obtained demographic, epidemiological, and microbiological data throughout the course of hospitalization and analyzed the cases of COVID-19 complicated by non-respiratory bacterial infections.
    Results: Of the 1914 patients included, non-respiratory bacterial infections with COVID-19 were diagnosed in 81 patients (4.2%). Of these, 59 (3.1%) were secondary infections. Bacteremia was the most frequent bacterial infection, occurring in 33 cases (55.9%), followed by urinary tract infections in 16 cases (27.1%). Staphylococcus epidermidis was the most common causative organism of bacteremia. Patients with COVID-19 with non-respiratory secondary bacterial infections had significantly higher mortality, and a multivariate logistic regression analysis demonstrated that those with bacteremia (aOdds Ratio = 15.3 [5.97-39.1]) were at higher risk of death. Multivariate logistic regression analysis showed that age, male sex, use of steroids to treat COVID-19, and intensive care unit admission increased the risk for nosocomial bacteremia.
    Conclusions: Secondary bacteremia is an important complication that may lead to poor prognosis in cases with COVID-19. An appropriate medical management strategy must be established, especially for patients with concomitant predisposing factors.
    Mesh-Begriff(e) Humans ; Male ; COVID-19/complications ; COVID-19/epidemiology ; Retrospective Studies ; Coinfection/epidemiology ; Bacteremia/drug therapy ; Bacteremia/epidemiology ; Bacteremia/microbiology ; Bacterial Infections/microbiology ; Mycoses/microbiology ; COVID-19 Testing
    Sprache Englisch
    Erscheinungsdatum 2023-01-20
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 1355399-9
    ISSN 1437-7780 ; 1341-321X
    ISSN (online) 1437-7780
    ISSN 1341-321X
    DOI 10.1016/j.jiac.2023.01.006
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5236: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang